Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

AstraZeneca lung drug gets ‘surprise’ win in COPD trials

 March 27, 2026

BioPharma Dive

The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.

Clinical DataRespiratoryRead full story

Post navigation

Novartis targets Xolair successor in buyout of startup Excellergy →
← Otsuka picks up PTSD drug with $700M Transcend buy

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com